Multiple Myeloma Clinical Trial Results

Browse clinical trials for Multiple Myeloma by phase, sponsor and reported results. Data from ClinicalTrials.gov.

• Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
  Phase 3 · National Cancer Institute (NCI) · Active, not recruiting · May 18, 2021
• Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
  Phase 3 · National Cancer Institute (NCI) · Active, not recruiting · Jul 1, 2013
• Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multi
  Phase 3 · National Cancer Institute (NCI) · Active, not recruiting · Jul 6, 2017
• Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Mu
  Phase 2 · University of Michigan Rogel Cancer Center · Active, not recruiting · Jul 28, 2026
• Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector C
  Phase 2 · University of Alabama at Birmingham · Completed · Jun 3, 2026
• Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma
  Early Phase 1 · M.D. Anderson Cancer Center · Active, not recruiting · Mar 20, 2020
• Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A
  Phase 2 · National Cancer Institute (NCI) · Active, not recruiting · Dec 10, 2024
• Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol
  Phase 2 · National Cancer Institute (NCI) · Active, not recruiting · Mar 19, 2025
• Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1
  Phase 2 · National Cancer Institute (NCI) · Active, not recruiting · Aug 2, 2023
• Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subp
  Phase 2 · National Cancer Institute (NCI) · Active, not recruiting · Aug 4, 2023
• A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Poma
  Phase 3 · Janssen Research & Development, LLC · Active, not recruiting · May 20, 2025
• A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES
  Phase 3 · Alexion Pharmaceuticals, Inc. · Active, not recruiting · Jul 2, 2026
• Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myel
  Phase 3 · National Cancer Institute (NCI) · Active, not recruiting · Jun 29, 2015
• Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Healt
  N/A · University of Alabama at Birmingham · Completed · Jul 2, 2026
• Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Partic
  Phase 3 · GlaxoSmithKline · Active, not recruiting · Oct 6, 2023

Trials by condition

Lung CancerNon-Small Cell Lung CancerBreast CancerColorectal CancerGastric CancerLiver CancerPancreatic CancerProstate CancerOvarian CancerMelanomaLeukemiaLymphomaMultiple MyelomaGlioblastomaType 2 DiabetesObesityHypertensionHeart FailureAtrial FibrillationStrokeChronic Kidney DiseaseNASH / MASHAlzheimer’s DiseaseParkinson’s DiseaseMultiple SclerosisDepressionEpilepsyALSRheumatoid ArthritisPsoriasisAtopic DermatitisCrohn’s DiseaseUlcerative ColitisLupusAsthmaCOPD

All trials